← FDA Drug Approvals (Drugs@FDA)
RETEVMO
NDA · New Drug Application · Sponsor: ELI LILLY AND CO · Approved 2024-04-10
Drug application
- FDA Application #
NDA218160- Application type
- New Drug Application
- Brand name
- RETEVMO
- Generic name
- SELPERCATINIB
- Active ingredients
- SELPERCATINIB
- Dosage form
- CAPSULE
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- ELI LILLY AND CO
- Manufacturer
- Eli Lilly and Company
- First approval
- 2024-04-10
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown